Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Tuesday, July 23rd. Cantor Fitzgerald analyst L. Watsek now forecasts that the biotechnology company will earn ($4.00) per share for the year, up from their prior forecast of ($4.39). Cantor Fitzgerald currently has a “Overweight” rating and a $173.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($5.57) per share.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). The firm had revenue of $103.11 million during the quarter, compared to analyst estimates of $85.72 million. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%.
Check Out Our Latest Research Report on Ascendis Pharma A/S
Ascendis Pharma A/S Price Performance
Shares of NASDAQ ASND opened at $134.01 on Thursday. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The business has a 50-day moving average price of $132.35 and a 200 day moving average price of $139.28.
Hedge Funds Weigh In On Ascendis Pharma A/S
Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Vestal Point Capital LP acquired a new position in Ascendis Pharma A/S during the fourth quarter worth $78,719,000. Price T Rowe Associates Inc. MD raised its holdings in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Ascendis Pharma A/S by 20.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after purchasing an additional 254,749 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after purchasing an additional 234,446 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in Ascendis Pharma A/S by 6.0% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock worth $507,658,000 after purchasing an additional 228,457 shares during the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- What Are the FAANG Stocks and Are They Good Investments?
- Enphase Energy Stock: Growth in the Renewable Energy Transition
- 3 Warren Buffett Stocks to Buy Now
- ASML Stock Nearing Bottom: Is Now the Time to Buy?
- ESG Stocks, What Investors Should Know
- Earnings Season Sell-Off: Is This Tech Giant a Buy?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.